poisar

Stocks · News reference

Novo Nordisk Announces U.S. Availability Of Awiqli, Its First Once-Weekly Basal Insulin For Adults With Type 2 Diabetes

BenzingaAug 11, 2026, 12:07 PMBenzinga Newsdesk

Awiqli® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing frequency of these weekly basal injections from seven to one per week1Awiqli® will be available at over 70,000

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Aug 11, 2026, 12:07 PM
Checked
Aug 11, 2026, 12:07 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading